Editing of the genome to correct disease-causing mutations is a promising approach for the treatment of human diseases. Recent advances in the development of programmable nuclease-based genome editing tools have substantially improved the ability to make precise changes in the human genome. Genome editing technologies are already being used to correct genetic mutations in affected tissues and cells to treat diseases that are refractory to traditional gene therapies. Chinese scientists have made remarkable breakthroughs in the field of therapeutic genome editing, particularly with the first clinical trial involving the clustered regularly interspaced short palindromic repeats-caspase 9 system that began in China. Herein, current progress toward developing programmable nuclease-based gene therapies is introduced, as well as future prospects and challenges in China.
Get full access to this article
View all access options for this article.
References
1.
NeufeldEF, SweeleyCC. Gene therapy for human genetic disease?. Science, 1972; 178:648–649.
2.
NaldiniL. Gene therapy returns to centre stage. Nature, 2015; 526:351–360.
3.
CohenJC, BoerwinkleE, MosleyTHJr, et al.Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New Engl J Med, 2006; 354:1264–1272.
4.
BarrangouR, DoudnaJA. Applications of CRISPR technologies in research and beyond. Nat Biotechnol, 2016; 34:933–941.
RouetP, SmihF, JasinM. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol Cell Biol, 1994; 14:8096–8106.
7.
FilippoJS, SungP, KleinH. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem, 2008; 77:229–257.
8.
WangJ, ExlineCM, DeClercqJJ, et al.Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotech, 2015; 33:1256–1263.
9.
De RavinSS, ReikA, LiuP-Q, et al.Targeted gene addition in human CD34+ hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat Biotech, 2016; 34:424–429.
10.
LiH, HaurigotV, DoyonY, et al.In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature, 2011; 475:217–221.
11.
AnguelaXM, SharmaR, DoyonY, et al.Robust ZFN-mediated genome editing in adult hemophilic mice. Blood, 2013; 122:3283–3287.
12.
HsuPD, LanderES, ZhangF. Development and applications of CRISPR-Cas9 for genome engineering. Cell, 2014; 157:1262–1278.
13.
SanderJD, JoungJK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol, 2014; 32:347–355.
14.
PattanayakV, LinS, GuilingerJP, et al.High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol, 2013; 31:839–843.
15.
KleinstiverBP, PrewMS, TsaiSQ, et al.Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature, 2015; 523:481–485.
16.
DoudnaJA, CharpentierE. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014; 346:1258096.
17.
WangHX, LiM, LeeCM, et al.CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem Rev, 2017; 117:9874–9906.
18.
DongZ, GeJ, LiK, et al.Heritable targeted inactivation of myostatin gene in yellow catfish (Pelteobagrus fulvidraco) using engineered zinc finger nucleases. PloS One, 2011; 6:e28897.
19.
ZhangC, WangL, RenG, et al.Targeted disruption of the sheep MSTN gene by engineered zinc-finger nucleases. Mol Biol Rep, 2014; 41:209–215.
20.
YaoY, NashunB, ZhouT, et al.Generation of CD34+ cells from CCR5-disrupted human embryonic and induced pluripotent stem cells. Hum Gene Ther, 2012; 23:238–242.
21.
QuX, WangP, DingD, et al.Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucl Acids Res, 2013; 41:7771–7782.
22.
ChenK, ShanQ, GaoC. An efficient TALEN mutagenesis system in rice. Methods, 2014; 69:2–8.
23.
ChenY, YuJ, NiuY, et al.Modeling Rett syndrome using TALEN-edited MECP2 mutant cynomolgus monkeys. Cell, 2017; 169:945–955.e10.
24.
KeQ, LiW, LaiX, et al.TALEN-based generation of a cynomolgus monkey disease model for human microcephaly. Cell Res, 2016; 26:1048–1061.
25.
DengHX, WangY, DingQR, et al.Gene therapy research in Asia. Gene Ther, 2017; 24:572–577.
26.
TebasP, SteinD, TangWW, et al.Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. New Engl J Med, 2014; 370:901–910.
27.
NormileD. China sprints ahead in CRISPR therapy race. Science, 2017; 358:20–21.
28.
LiangP, XuY, ZhangX, et al.CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell, 2015; 6:363–372.
29.
LiangP, DingC, SunH, et al.Correction of β-thalassemia mutant by base editor in human embryos. Protein Cell, 2017; 8:811–822.
30.
ZhouC, ZhangM, WeiY, et al.Highly efficient base editing in human tripronuclear zygotes. Protein Cell, 2017; 8:772–775.
31.
KangX, HeW, HuangY, et al.Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing. J Assist Reprod Genet, 2016; 33:581–588.
32.
NiuD, WeiHJ, LinL, et al.Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. Science, 2017; 357:1303–1307.
33.
SaadatpourZ, BjorklundG, ChirumboloS, et al.Molecular imaging and cancer gene therapy. Cancer Gene Ther, 2016Nov18 [Epub ahead of print]; DOI: 10.1038/cgt.2016.62.
34.
KershawMH, WestwoodJA, DarcyPK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer, 2013; 13:525–541.
35.
RibasA. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov, 2015; 5:915–919.
36.
KochenderferJN, RosenbergSA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol, 2013; 10:267–276.
37.
ParkTS, RosenbergSA, MorganRA. Treating cancer with genetically engineered T cells. Trends Biotechnol, 2011; 29:550–557.
38.
LiuX, ZhangY, ChengC, et al.CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res, 2017; 27:154–157.
39.
LiangC, LiF, WangL, et al.Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials, 2017; 147:68–85.
40.
LiuY, ZhanY, ChenZ, et al.Directing cellular information flow via CRISPR signal conductors. Nat Methods, 2016; 13:938–944.
41.
LiL, SongL, LiuX, et al.Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice. ACS Nano, 2017; 11:95–111.
42.
YangY, WangL, BellP, et al.A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol, 2016; 34:334–338.
43.
WangL, YangY, WhiteJ, et al.Crispr/Cas9-mediated in vivo gene targeting corrects haemostasis in newborn and adult FIX-KO mice. Blood, 2016; 128:1174–1174.
44.
GuanY, MaY, LiQ, et al.CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol Med, 2016; 8:477–488.
DengJ, PengWL, LiJ, et al.Successful preimplantation genetic diagnosis for alpha- and beta-thalassemia in China. Prenat Diagn, 2006; 26:1021–1028.
47.
KawamataS, KanemuraH, SakaiN, et al.Design of a tumorigenicity test for induced pluripotent stem cell (iPSC)-derived cell products. J Clin Med, 2015; 4:159–171.
48.
SongB, FanY, HeW, et al.Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. Stem Cells Devel, 2015; 24:1053–1065.
49.
YangY, ZhangX, YiL, et al.Naive induced pluripotent stem cells generated from beta-thalassemia fibroblasts allow efficient gene correction with CRISPR/Cas9. Stem Cells Transl Med, 2016; 5:8–19.
50.
MaN, ShanY, LiaoB, et al.Factor-induced reprogramming and zinc finger nuclease-aided gene targeting cause different genome instability in beta-thalassemia induced pluripotent stem cells (iPSCs). J Biol Chem, 2015; 290:12079–12089.
51.
NiuX, HeW, SongB, et al.Combining single strand oligodeoxynucleotides and CRISPR/Cas9 to correct gene mutations in beta-thalassemia-induced pluripotent stem cells. J Biol Chem, 2016; 291:16576–16585.
52.
XuP, TongY, LiuXZ, et al.Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C>T) mutation in beta-thalassemia-derived iPSCs. Sci Rep, 2015; 5:12065.
53.
OuZ, NiuX, HeW, et al.The combination of CRISPR/Cas9 and iPSC technologies in the gene therapy of human beta-thalassemia in mice. Sci Rep, 2016; 6:32463.
54.
HeQ, WangHH, ChengT, et al.Genetic correction and hepatic differentiation of hemophilia B-specific human induced pluripotent stem cells. Chin Med Sci J, 2017; 32:135–144.
55.
TangZH, ChenJR, ZhengJ, et al.Genetic correction of induced pluripotent stem cells from a deaf patient with MYO7A mutation results in morphologic and functional recovery of the derived hair cell-like cells. Stem Cells Transl Med, 2016; 5:561–571.
56.
ChenJR, TangZH, ZhengJ, et al.Effects of genetic correction on the differentiation of hair cell-like cells from iPSCs with MYO15A mutation. Cell Death Differ, 2016; 23:1347–1357.
57.
GuoD, LiuH, GaoG, et al.Creating a patient carried Men1 gene point mutation on wild type iPSCs locus mediated by CRISPR/Cas9 and ssODN. Stem Cell Res, 2017; 18:67–69.
58.
WuY, LiangD, WangY, et al.Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell, 2013; 13:659–662.
59.
ZhuJ, MingC, FuX, et al.Gene and mutation independent therapy via CRISPR-Cas9 mediated cellular reprogramming in rod photoreceptors. Cell Res, 2017; 27:830–833.
60.
WangL, YiF, FuL, et al.CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. Protein Cell, 2017; 8:365–378.
61.
XieC, ZhangYP, SongL, et al.Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome. Cell Res, 2016; 26:1099–1111.
62.
LiuJ, GaoC, ChenW, et al.CRISPR/Cas9 facilitates investigation of neural circuit disease using human iPSCs: mechanism of epilepsy caused by an SCN1A loss-of-function mutation. Transl Psychiatry, 2016; 6:e703.
63.
AndreF. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine, 2000; 18:S20–22.
64.
LiH, ShengC, WangS, et al.Removal of integrated hepatitis B virus DNA using CRISPR-Cas9. Front Cell Infect Microbiol, 2017; 7:91.
65.
LiH, ShengC, LiuH, et al.An effective molecular target site in hepatitis B virus S gene for Cas9 cleavage and mutational inactivation. Int J Biol Sci, 2016; 12:1104–1113.
66.
LiuX, HaoR, ChenS, et al.Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J Gen Virol, 2015; 96:2252–2261.
67.
JiangC, MeiM, LiB, et al.A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. Cell Res, 2017; 27:440–443.
68.
PiotP, BartosM, LarsonH, et al.Coming to terms with complexity: a call to action for HIV prevention. Lancet, 2008; 372:845–859.
69.
XuL, YangH, GaoY, et al.CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Mol Ther, 2017; 25:1782–1789.
70.
YuS, YaoY, XiaoH, et al.Simultaneous knockout of CXCR4 and CCR5 genes in CD4+ T cells via CRISPR/Cas9 confers resistance to noth X4- and R5-tropic human immunodeficiency virus type 1 infection. Hum Gene Therapy, 2018; 29:51–67.
71.
ZouZ, HuangK, WeiY, et al.Construction of a highly efficient CRISPR/Cas9-mediated duck enteritis virus-based vaccine against H5N1 avian influenza virus and duck Tembusu virus infection. Sci Rep, 2017; 7:1478.
72.
LinC, LiH, HaoM, et al.Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing of HSV-1 virus in human cells. Sci Rep, 2016; 6:34531.
ShaoY, GuanY, WangL, et al.CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. Nat Protoc, 2014; 9:2493–2512.
75.
ZuoE, CaiYJ, LiK, et al.One-step generation of complete gene knockout mice and monkeys by CRISPR/Cas9-mediated gene editing with multiple sgRNAs. Cell Res, 2017; 27:933–945.
76.
WangL, LiMY, QuC, et al.CRISPR-Cas9-mediated genome editing in one blastomere of two-cell embryos reveals a novel Tet3 function in regulating neocortical development. Cell Res, 2017; 27:815–829.
77.
EkserB, EzzelarabM, HaraH, et al.Clinical xenotransplantation: the next medical revolution?. Lancet, 2012; 379:672–683.
78.
DennerJ. How active are porcine endogenous retroviruses (PERVs)?. Viruses, 2016; 8.
79.
YangL, GuellM, NiuD, et al.Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science, 2015; 350:1101–1104.
80.
BenamKH, DauthS, HassellB, et al.Engineered in vitro disease models. Annu Rev Pathol, 2015; 10:195–262.
81.
SchanenNC, KurczynskiTW, BrunelleD, et al.Neonatal encephalopathy in two boys in families with recurrent Rett syndrome. J Child Neurol, 1998; 13:229–231.
82.
JenningsCG, LandmanR, ZhouY, et al.Opportunities and challenges in modeling human brain disorders in transgenic primates. Nat Neurosci, 2016; 19:1123–1130.
83.
HuangL, HuaZ, XiaoH, et al.CRISPR/Cas9-mediated ApoE–/– and LDLR–/– double gene knockout in pigs elevates serum LDL-C and TC levels. Oncotarget, 2017; 8:37751–37760.
84.
FuY, FodenJA, KhayterC, et al.High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol, 2013; 31:822–826.
